Antisense therapies for cancer bridging the pharmacogenomic divide

Drug Discovery Today: Therapeutic Strategies

Volumn 10, Issue 3, 2013, Pages e157-e163

  Robert MacLeod, A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903360498     PISSN: None     EISSN: 17406773     Source Type: Journal    
DOI: 10.1016/j.ddstr.2013.04.002     Document Type: Review

References (42)

1. Nekrutenko, A. and Taylor, J. (2012) Next-generation sequencing data interpretation: enhancing reproducibility and accessibility. Nat. Rev. Genet. 13, 667-672
2. Chin, L. and Gray, J.W. (2008) Translating insights from the cancer genome into clinical practice. Nature 452, 533-563
3. Kim, H. et al. (2010) Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc. Natl. Acad. Sci. U.S.A. 107, 2183-2188
4. Yang, Y. et al. (2011) Integrated bioinformatics analysis for cancer target identification. Methods Mol. Biol. 719, 527-545
5. Weinstein, I.B. and Joe, A. (2008) Oncogene addiction. Cancer Res. 68, 3077-3080
6. Torti, D. and Trusolino, L. (2011) Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol. Med. 3, 623-636
7. Herbst, R.S. et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 22, 785-794
8. Quintas-Cardama, A. et al. (2009) Imatinib and beyond - exploring the full potential of targeted therapy for CML. Nat. Rev. Clin. Oncol. 6, 535-543
9. Shaw, A.T. et al. (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012
10. Flaherty, K.T. et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 9, 809-819
11. Eddy, S.R. (2001) Non-coding RNA genes and the modern RNA world. Nat. Rev. Genet. 2, 919-929
12. Garzon, R. et al. (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9, 775-789
13. Crooke, S.T. (2013) RNA directed therapeutics: mechanisms and status. Drug Discov. Today: Ther. Strat. http://dx.doi.org/10.1016/j.ddstr.2012.12.001
14. Raal, F.J. et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Lancet 375, 998-1006
15. Saad, F. et al. (2011) Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin. Cancer Res. 17, 5765-5773
16. Geary, R.S. (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug Metab. Toxicol. 4, 381-391
17. Ackermann, E.J. et al. (2012) Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19, 43-44
18. Younis, H.S. et al. (2012) Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood 10, 2401-2408
19. Zanardi, T.A. et al. (2012) Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J. Pharmacol. Exp. Ther. 2, 489-496
20. Southwell, A.L. et al. (2012) Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol. Med. 11, 634-643
21. Chi, K.N. et al. (2008) A phase I study of OGX-011, a 20-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin. Cancer Res. 14, 833-839
22. Talbot, D.C. et al. (2010) Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin. Cancer Res. 24, 6150-6158
23. Wheeler, T.M. et al. (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115
24. Seth, P.P. et al. (2010) Synthesis and biophysical evaluation of 20,40-constrained 20O-methoxyethyl and 20,40-constrained 20O-ethyl nucleic acid analogues. J. Org. Chem. 5, 1569-1581
25. Bennett, C.F. and Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293
26. Geary, R.S. et al. (2001) Pharmacokinetic properties of 20-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 3, 890-897
27. Hong, D.S. (2011) A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res. 20, 6582-6591
28. Bogdahn, U. et al. (2011) Targeted therapy for high-grade glioma with the TGF-b2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncology 1, 132-142
29. Li, F. et al. (1999) Pleiotropic cell-division defects and apoptosis induced by interference with surviving function. Nat. Cell Biol. 1, 461-466
30. Talbot, D.C. et al. (2010) Tumor surviving is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin. Cancer Res. 16, 6150-6158
31. Gleave, M. et al. (2002) Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev. 21, 79-92
32. Zellweger, T. et al. (2001) Chemosensitization of human renal cell cancer using antisense oligonucleotides target the antiapoptotic gene clusterin. Neoplasia 3, 360-367
33. Zhang, H. et al. (2005) Clusterin inhibits apoptosis by interacting with Bax. Nat. Cell Biol. 7, 909-915
34. Zoubeidi, A. et al. (2010) Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol. Cancer Res. 8, 119-130
35. Redondo, M. et al. (2000) Over expression of clusterin in human breast carcinoma. Am. J. Pathol. 157, 393-399
36. Miyake, H. et al. (2002) Over expression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 59, 150-154
37. Miyake, H. et al. (2002) Over expression of clusterin in an independent prognostic factor for nonpapillary renal cell carcinoma. J. Urol. 167, 703-706
38. Chen, X. et al. (2003) Clusterin as a biomarker in murine and human intestinal neoplasia. Proc. Natl. Acad. Sci. U.S.A. 100, 9530-9535
39. Steinberg, J. et al. (1997) Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 3, 1707-1711
40. July, L.V. et al. (2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50, 179-188
41. Chi, K.N. et al. (2005) A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 20methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer 97, 1287-1296
42. Chi, K.N. et al. (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 4247-4254